New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 8, 2013
18:58 EDTJCP, GILD, STWD, SHLM, STAA, OCZ, AAOn The Fly: After Hours Movers
UP AFTER EARNINGS: Staar Surgical (STAA), up 21% after the company announced preliminary Q1 revenue that beat current estimates... ALSO HIGHER: Gilead (GILD), up 2% after submitting an new drug application to the FDA for its hepatitis C treatment sofosbuvir... DOWN AFTER EARNINGS: Alcoa (AA), down 1.7%... A. Schulman (SHLM), down 5.8%... ALSO LOWER: J.C. Penney (JCP), down 6.8% after the company announced CEO Ron Johnson was stepping down and will be replaced by former CEO Myron "Mike" Ullman... OCZ Technology (OCZ), down 12% after the company announced it would not meet an April 8 filing deadline with the SEC... Starwood Property (STWD), down 2.6% after announcing 26.5M common share offering.
News For STAA;GILD;AA;SHLM;JCP;OCZ;STWD From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | all recent news | >>
April 8, 2015
15:24 EDTAANotable companies reporting after market close
Subscribe for More Information
14:29 EDTAAAlcoa technical comments ahead of results
Subscribe for More Information
14:12 EDTAAAlcoa April weekly 13 straddle priced for 5% movement into Q1
Subscribe for More Information
09:45 EDTAAEarnings Watch: Alcoa sentiment mixed ahead of Q1 results
Subscribe for More Information
09:35 EDTAAActive equity options trading on open
Subscribe for More Information
07:48 EDTAAAlcoa April volatility elevated into Q1 and outlook
Alcoa April weekly call option implied volatility is at 58, April is at 42, May is 38, June is at 35, October is at 34; compared to its 26-week average of 34 according to Track Data, suggesting large April price movement into its expected release of Q1 results on April 8.
April 7, 2015
17:58 EDTGILDGilead submits NDA for investigational combination for treatment of HIV-1
Subscribe for More Information
16:00 EDTGILDOptions Update; April 7, 2015
Subscribe for More Information
09:35 EDTAAActive equity options trading on open
Subscribe for More Information
09:09 EDTSHLMA. Schulman plans to establish new Masterbatch production plant in Turkey
A. Schulman announced plans to establish a new Masterbatch production plant in Turkey. This new facility will produce, when fully operational, approximately 40M pounds of the Company's premium additive, white, and breathable masterbatches for food and industrial packaging customers in Turkey and other countries in the Middle East and North Africa. The Company plans to lease existing industrial facilities in the greater Istanbul area, which it will convert into a state-of-the-art production plant at a cost projected to be in the EUR5M-EUR7M range. This new facility is expected to be in production by the end of FY16.
April 6, 2015
19:27 EDTSHLMOn The Fly: After Hours Movers
Subscribe for More Information
16:58 EDTSHLMA. Schulman reports Q2 adjusted EPS 39c, consensus 40c
16:56 EDTSHLMA. Schulman backs FY15 adjusted EPS view $2.50-$2.55, consensus $2.48
Guidance does not include the impact of the previously announced acquisition of Citadel Plastics, which is expected to close on track in the third quarter.
16:45 EDTSHLMA. Schulman slips lower after results, levels to watch
Subscribe for More Information
16:40 EDTSHLMA. Schulman reports Q2 EPS (3c), may not compare to consensus 40c
Reports Q2 revenue $542.3M, one estimate $579.4M.
15:16 EDTSHLMNotable companies reporting after market close
Subscribe for More Information
09:09 EDTSHLMA. Schulman promotes Kristopher Westbrooks to Chief Accounting Officer
Subscribe for More Information
07:42 EDTAAAlcoa April volatility elevated into Q1 and outlook
Subscribe for More Information
07:36 EDTGILDGilead Q1 HCV revenue poised to beat expectations, says RBC Capital
After analyzing weekly prescription data, RBC Capital believes that Gilead's weekly hepatitis C prescriptions are tracking towards $3.5B-$3.6B of revenue from hepatitis C drugs for Q1, versus the consensus outlook of about $2.6B. The firm keeps an Outperform rating on Gilead.
April 5, 2015
14:43 EDTGILDActavis seeks FDA approval to market generic version of Gilead's Letairis
Actavis (ACT) on Friday, confirmed that it has filed an Abbreviated New Drug Application with the FDA seeking approval to market Ambrisentan Tablets, 5 mg and 10 mg. Actavis' ANDA product is a generic version of Gilead Science's (GILD) Letairis, which is a treatment for pulmonary arterial hypertension. Gilead Sciences and Royalty Pharma Collection Trust filed suit against Actavis on April 1, in the U.S. District Court for the District of Delaware seeking to prevent Actavis from commercializing its ANDA product prior to the expiration of U.S. Patent number RE42,462. The lawsuit was filed under the provisions of the Hatch-Waxman Act, resulting in a stay of final FDA approval of Actavis' ANDA for up to 30 months from the date the plaintiffs received notice of Actavis' ANDA filing or until final resolution of the matter before the court, whichever occurs sooner, subject to any other exclusivities. Based on available information, Actavis believes it may be a "first applicant" to file an ANDA for the generic version of Letairis and, should its ANDA be approved, may be entitled to 180 days of generic market exclusivity. For the 12 months ending December 31, Letairis had global sales of approximately $595M, according to Gilead.
1 | 2 | 3 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use